Transgene (Euronext : TNG)
Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer.
Investor Relations Contact
investorrelations@transgene.fr
Financial information
Key figures
| In € million except share and per share data | 2023 | 2022 | 2021 | 2020 | 2019 |
| Revenue | 7.9 | 10.3 | 17.4 | 9.9 | 13.7 |
| R&D Expense | -29.6 | -32.2 | -32.9 | -27.3 | -31.4 |
| G&A Expense | -7.0 | -7.9 | -7.4 | -6.5 | -7.1 |
| Net income (loss) | -22.3 | -32.8 | -19.5 | -17.2 | -18.8 |
| Net Cash Burn | -24.0 | -22.8 | -10.0 | -17.0 | -20.5 |
| Cash & Cash Equivalents | 15.7 | 26.8 | 49.6 | 26.3 | 43.3 |
| Earnings/Loss per Share (Basic) | -0.22 | -0.33 | -0.21 | -0.21 | -0.23 |
| Earnings/Loss per Share (Diluted) | -0.22 | -0.33 | -0.20 | -0.21 | -0.23 |
| Shares Outstanding | 100,852,742 | 100,204,071 | 97,771,334 | 83,841,334 | 83,265,464 |
Financial reports
| Years | Quarter | Interim | Registration Document | |||
|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | |||
| 2024 | ||||||
| 2023 | XBRL(fr) Amendment(fr) | |||||
| 2022 | XBRL(fr) | |||||
| 2021 | XBRL(fr) | |||||
| 2020 | ||||||
| 2019 | ||||||
| 2018 | ||||||
| 2017 | ||||||
| 2016 | ||||||
| 2015 | ||||||
| 2014 | ||||||
Regulated information
Monthly information on shares outstanding and voting rights (in French)
Share buyback program (in French)
Liquidity contract related information
Half-year report on the Transgene liquidity contract
- 2024: at June 30, 2024
- 2023: at December 31, 2023; at June 30, 2023
- 2022: at December 31, 2022; at June 30, 2022
- 2021: at December 31, 2021; at June 30, 2021
- 2020: at December 31, 2020; at June 30, 2020
- 2019: at December 31, 2019; at June 30, 2019
- 2018: at December 31, 2018; at June 30, 2018
- 2017: at December 31, 2017; at June 30, 2017
- 2016: at December 31, 2016; at June 30, 2016
Chairman’s report on corporate governance and internal controls
- Universal Registration Document 2023 (page 63)
- Universal Registration Document 2022 (page 63)
- Universal Registration Document 2021 (page 73)
- Universal Registration Document 2023 (page 246)
- Universal Registration Document 2022 (page 240)
- Universal Registration Document 2021 (page 220)
Annual General Meeting information
- May 5, 2023: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 25, 2022: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 26, 2021: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 27, 2020: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 22, 2019: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 23, 2018: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 8, 2017: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- May 24, 2016: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 11, 2015: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
- June 18, 2014: Notice of meeting – Results of the vote – Minutes of the combined general meeting (in French)
Rights issue
Stock information
General
General
| Stock Market | Euronext Paris – Eurolist (compartiment C) |
| Reuters / Bloomberg | TRNG.PA / TNG.FP |
| ISIN Code | FR0005175080 |
| Total number of shares outstanding | 132,293,932 |
| Initial Public Offering (IPO) | March 26, 1998 |
| Local Sector Index | Next Biotech |
| Financial Year Ends | December 31 |
Analysts
| Company | Analyst | Phone | |
|---|---|---|---|
| Cantor Fitzgerald | Brandon Folkes | brandon.folkes@cantor.com | +1 212-294-8081 |
| Intron Health | Naresh Chouhan | naresh@intronhealthresearch.com | +44 207 375 9143 |
| Invest Securities | Jamila El Bougrini | jelbougrini@invest-securities.com | +33 (0)1 44 88 88 09 |
| Kempen & Co. | Suzanne van Voorthuizen | suzanne.vanvoorthuizen@kempen.com | +31 (0)20 348 8484 |
| Oddo BHF | Martial Descoutures | martial.descoutures@oddo-bhf.com | +33 (0)1 44 51 85 00 |
Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.
Investor Events & Presentations
Webcasts
- October 14, 2024 - TG4001+Avelumab vs Avelumab Single-Agent Phase II Update
- September 20, 2023 - 2023 Half-year results and business update
- May 5, 2023 - New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
- March 16, 2023 - 2022 Full-year results and business update
- September 27, 2022 - Transgene R&D Day (Paris, France)
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- November 12, 2020 - Detailed results of the Phase 1b/2 trial of TG4001 and avelumab in advanced HPV-positive cancers presented at SITC 2020
Financial calendar
- March 27, 2024 - 2023 Fiscal Year Results
- May 14, 2024 - First Quarter 2024 Financial Results
- May 15, 2024 - Annual Shareholders’ Meeting
- September 24, 2024 - First Half 2024 Financial Results
- November 7, 2024 - Third Quarter 2024 Financial Results
Investor events
- January 15, 2024 - Oddo BHF Forum – January 15 & 16, 2024
- January 30, 2024 - Invest Securities Biomed Forum – January 30, 2024
- April 5, 2024 - Investor Access Event – April 5, 2024
- April 16, 2024 - Van Lanschot Kempen Life Sciences Conference (Amsterdam, Netherlands)- April 16, 2024
- June 6, 2024 - Oddo BHF Nextcap Forum – June 6, 2024
- September 17, 2024 - HealthTech Innovation Days (HTID) – Paris – September 17-18, 2024
- October 15, 2024 - Investor Access Forum, October 15 & 16, 2024
Annual General Meeting
Annual General Meeting of May 15, 2024
2024 ORDINARY AND EXTRAORDINARY MEETING
Location TRANSGENE 400 boulevard Gonthier d’Andernach – Parc d’Innovation 67400 ILLKIRCH-GRAFFENSTADEN – FRANCE
Date and Time 15 May 2024 at 10 am – Retransmission (live and deferred)
Webcast link to French language conference call
Please log in to the following link to obtain your personal telephone IDs.
Documents:
- Notice of the 2024 General Shareholder’s Meeting
- French BALO publication, including resolutions (in French)
- Presentation on draft resolutions
- Ballot (in French)
- Universal Registration Document 2023
- Information regarding the total number of the outstanding shares and voting rights of the Company (Article R. 225-73-1 du French Commercial code)
